Kromek is pioneering digital colour imaging for x-rays and has brought ground-breaking innovation to materials technology and advanced 3D imaging, that will literally change the way in which we see the world.


The Company specialises in making semiconductor materials within the Cadmium Telluride family. These materials have significant applications as detectors of x-rays and gamma rays, notably in medical imaging, security screening, industrial inspection and space exploration, allowing for very precise identification of materials.



Cadmium Zinc Telluride is also the material of choice as a substrate for the fabrication of infrared detectors in both civilian and military markets. In addition to its range of semiconductor materials, detector packages and non imaging detection systems Kromek also supplies x-ray imaging packages with multi view capabilities.

These x-ray display platforms provide real 3D x-ray imaging for the first time without specialist viewing equipment. When photogrammetric algorithms are applied to these images, three dimensional co-ordinate data is produced.

Kromek Group is listed on London's alternative Investment Market, AIM. Its ordinary shares carry the symbol KMK. Kromek Group plc is incorporated in England and Wales under the Companies Act 2006 (registration number 8661469). Its main countries of operation are the United Kingdom and the United States.

http://www.kromek.com/

I've put it on my watchlist!😃

:-))

Final Results
RNS
RNS Number : 3547J
Kromek Group PLC
28 June 2017
 
28 June 2017
 
Kromek Group plc
("Kromek" or the "Group")
 
Final Results for the Year ended 30 April 2017
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, announces its final audited results for the year ended 30 April 2017.
 
Financial Highlights
·     Revenue increased 7.5% to £9.0m (2015/16: £8.3m)
·     Product sales accounted for 74% of total revenues (2015/16: 65%), a growth year-on-year of 23%
·     Gross margin was 57% (2015/16: 53%)
·     Administration costs (including operating expenses) were £8.7m (2015/16: £8.3m)
·     EBITDA* was £1.5m loss (2015/16: £2.4m loss), following further investment of £3.5m (2015/16: £3.2m) of research costs expensed in preparation for the expected demand regarding D3S and SPECT
·     Loss before tax for the year was £3.8m (2015/16: £4.1m loss)
·     Total proceeds of £21m (£20m net of expenses) were raised as part of a Placing and Open Offer in February 2017, which saw a further 105,129,536 ordinary shares issued 
·     Cash and cash equivalents at 30 April 2017 were £20.3m (30 April 2016: £3.9m)
*EBITDA defined as earnings before interest, taxation, depreciation, amortisation and share-based payments.
 
Operational Highlights
Another year of good progress and ramp-up in commercial activities with revenue growth driven by higher product sales across Kromek's three key target markets.
 
Medical Imaging 
·     Commenced delivery on $12.6m five-year OEM contract to supply detectors for BMD diagnostics systems
·     Awarded repeat contracts by three current BMD customers worth $1.2m in total
·     Won contract worth minimum of $560,000 for the supply of radiation detectors with an existing customer
·     Continued to make progress on the development of CZT-based SPECT modules for customer in China
 
Nuclear Detection
·     Delivered 10,000 D3S units in support of DARPA's SIGMA programme
o D3S sensors were field-tested in Washington DC and currently deployed by New Jersey Port Authority
·     Awarded $1.6m two-year agreement from DTRA to develop a ruggedised high performance isotope radiation detector for military use
·     Won and delivered a $430,000 contract to supply nuclear radiation detection products to the UK Ministry of Defence
 
Security Screening
·     Secured five-year agreement, worth a minimum of $3.1m, from an existing US-based customer
·     Awarded 12-month contract, valued at $990,000, together with a ten-year exclusivity agreement, by an existing US-based customer to develop and supply upgraded detectors
·     Awarded and delivered a contract for the Group's bottle scanners from an Asian airport group 
 
Six new patents were filed and 11 granted during the period.
 
Dr Arnab Basu, CEO of Kromek, said: "We are pleased with the growth in revenues this year, reflecting the delivery of long-term contracts won in previous years and contracts won during the year. Kromek is at the leading-edge in developing commercially-viable radiation detection solutions and this has, in turn, enabled our customers to successfully launch their new generation of clearly differentiated products in a wide range of markets. Consequently, revenues from the sale of our products now accounts for nearly three quarters of our revenues.
 
"In the 2017/18 fiscal year, Kromek is seeing a step change across all its business segments as we continue to execute on the large-scale contracts that have been secured over the last 24 months. Additionally, we expect OEM customers to launch products incorporating our technology, prompting additional orders to be placed as sales of these products accelerate. As a result, the Group expects to report year-on-year revenue growth of approximately 40%, in-line with market expectations."

Out before close, not good enough.

Down by over a third in the last year , but results out today look encouraging.

2 July 2018

Kromek Group plc

("Kromek" or the "Group")



Final Results for the Year ended 30 April 2018



Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, announces its final audited results for the year ended 30 April 2018.



Financial Highlights

· Revenue increased 32% to £11.8m (2016/17: £9.0m)

· Product sales accounted for 81% of total revenues (2016/17: 74%), a growth year-on-year of 44%

· Gross margin was 56.4% (2016/17: 57.1%)

· EBITDA* was £0.5m profit (2016/17: £1.5m loss)

· Loss before tax for the year was £2.5m (2016/17: £3.8m loss)

· Cash and cash equivalents at 30 April 2018 were £9.5m (31 October 2017: £15m)

*EBITDA defined as earnings before interest, taxation, depreciation, amortisation, other income and share-based payments. For a reconciliation, see the Financial Review below.



Operational Highlights



· Milestone year as revenue growth from ramp-up in commercial activities enabled Kromek to achieve EBITDA positive for the first time

· Growth due to continued delivery on previously-signed agreements as well as commencing delivery on new high-value contracts won during the year

· Secured new purpose-built premises for Kromek's US operations in Pittsburgh, which will enable the facility to become a world-leading manufacturer of SPECT cameras



Medical Imaging

The Group's CZT-based SPECT cameras and BMD detectors produce superior quality and higher resolution digital images that significantly advance the early identification of disease, such as cancer, dementia and osteoporosis.

· Secured a five-year contract, worth a minimum of $5.38m, to incorporate Kromek's CZT-based detector modules in a new osteoporosis product offering for an existing BMD customer

· Awarded a three-year £1.4m programme by Innovate UK to deliver a Low Dose Molecular Breast Imaging Device based upon the Group'-s CZT-based SPECT detectors

· Won a five-year repeat order, post-period end, worth $1.2m, from an existing medical customer for the supply of gamma detector modules for incorporation in the customer's products

· Advanced towards achieving first clinical validation of Kromek's CZT-based SPECT detector system



Nuclear Detection

The D3S is the world's most advanced, portable, nuclear radiation detection device used by counter-terrorist agencies to protect civilians and key infrastructure in cities, including ports, borders and transport hubs. Kromek's portfolio also includes a range of high resolution detectors and measurement systems for the civil nuclear markets used in nuclear power plants, research and for other applications.

· Awarded a $1.6m extension to its DARPA contract to add further technical innovation capability to the Kromek D3S family of equipment

· D3S continued to be deployed and field-tested in major areas in the US by DARPA, and by other public administrations across the globe, including by European authorities during the visit of the President of the United States to Brussels in May 2017

· Named as a qualified contractor under the $8.2bn U.S. Department of Defense IDIQ for the Joint Enterprise - Research, Development, Acquisition, and Production/Procurement contract award vehicle following extensive due diligence

· Strengthening and expansion of distribution channels in the civil nuclear markets, and completion of deployment of Quant for GR1 product in all UK EDF nuclear power plants



Security Screening

The Group's security screening solutions are being incorporated into the next generation liquid and luggage scanners. These upgraded machines are replacing legacy machines and are enhancing the safety of passengers while minimising the inconvenience of the security process at airports.

· Commenced work on the Group's first long-term security screening contract: a five-year, $3.1m agreement with an existing US-based customer to provide OEM components for baggage screening products used in aviation security

· Won a five-year, $2.0m contract, from a new OEM customer, which has commenced incorporating Kromek's technology into its baggage security screening systems to enhance detection of an extensive range of threat materials



Seven new patents were filed and 29 granted during the period.



Dr Arnab Basu, CEO of Kromek, said: "I am very pleased to report that Kromek had another good year of delivering revenue growth and developing our customer base who continue to launch next generation products incorporating our advanced radiation detectors. We also achieved one of our key targets for the year by becoming EBITDA positive for the first time in our history. This is an important milestone towards cash flow breakeven and pre-tax profits.



"Looking ahead, the momentum of the 2017/18 financial year has been sustained into the current financial year as Kromek's products continue to gain traction in all of our target markets from the increasing adoption of CZT-based technology and other products. We continue to win new customers and, together with executing on previously-won contracts, Kromek expects to deliver growth across its business segments and to report continued revenue growth for 2018/19 in line with market expectations."

Kromek wins two new contracts in medical division
RNS
RNS Number : 2245Y
Kromek Group PLC
20 August 2018

20 August 2018

Kromek Group plc
("Kromek" or the "Company")

Kromek wins two new contracts in medical division
New OEM customer and a repeat contract from existing BMD customer underscores momentum in medical imaging sector

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that it has secured two contracts, worth a total of $1 million, with a new OEM customer and an existing Bone Mineral Densitometry (BMD) customer. Both contracts commence immediately, with one delivered over an 18-month period and the other within the current financial year.

In the nuclear medicine instrumentation field, Kromek has been awarded a $700k order from a new OEM customer to supply its proprietary Cadmium Zinc Telluride (CZT) detectors to be used in the nuclear medicine market. The Company's technology will provide higher resolution detection capabilities enabling better patient outcomes. This contract will be delivered over an 18-month period starting immediately.

In the Bone Mineral Densitometry market, Kromek has received a repeat contract of $340k for CZT-based detectors for the customer's existing product line. This further re-enforces the run rate of this product group with all revenue from this contract to be recorded in the current financial year.

Dr Arnab Basu, CEO of Kromek, commented: "We continue to add new OEM customers in the medical device sector, working with them to build the next generation of medical instrumentation. Our CZT technology in medical scanners delivers excellent quality images and detection capability that lead to a better patient outcome. We also build strong and long-lasting partnerships with our clients, as highlighted by today's repeat contract with another OEM in the BMD sector to supply CZT-based detection units for their equipment."